BQ Blue’s special research section collates quality and in-depth equity and economy research reports from across India’s top brokerages, asset managers and research agencies. These reports offer BloombergQuint’s subscribers an opportunity to expand their understanding of companies, sectors and the economy.
Dolat Capital Report
Sun Pharmaceutical Industries Ltd. reported a stellar Q2 primarily driven by higher domestic growth aptly supported by specialty sales in the U.S.
Revenue growth of 13% YoY was in-line with estimates while profits at Rs 21 billion were 20% above estimate driven by $10 million milestone payment from U.S. specialty sales, lower research and development spend and lower tax outgo.
Gross margins at 73.6% (high contribution from U.S.), controlled spend aided adjusted for milestone income, Ebitda margins at 27.6% (150 basis points beat, reported 28%).
Debt reduction of $209 million in H1 FY21 led to lower interest outgo.
Sun Pharma added ‘Winlevi’ to its specialty portfolio (in-licensing deal for U.S.) strengthening its derma franchise.
Click on the attachment to read the full report:
DISCLAIMER
This report is authored by an external party. BloombergQuint does not vouch for the accuracy of its contents nor is responsible for them in any way. The contents of this section do not constitute investment advice. For that you must always consult an expert based on your individual needs. The views expressed in the report are that of the author entity and do not represent the views of BloombergQuint.
Users have no license to copy, modify, or distribute the content without permission of the Original Owner.
As a Subscriber you get
Stories
RECOMMENDED FOR YOU
POPULAR